CK 17 - CAS 86727-00-6
Catalog number: 86727-00-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H15BrN2OS
Molecular Weight:
375.29
COA:
Inquire
Targets:
Interleukin Related
Description:
CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation.
Purity:
98%
Appearance:
Powder
Synonyms:
CK 17; CK17; CK-17; 5-Bromotetrahydro-5-methyl-3-phenyl-2-(phenylimino)-4H-1,3-thiazin-4-one
Solubility:
Soluble in DMSO
Storage:
-20℃ Freezer
MSDS:
Inquire
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
ASZBPWIGUHLPML-MNDPQUGUSA-N
InChI:
1S/C17H15BrN2OS/c1-17(18)12-22-16(19-13-8-4-2-5-9-13)20(15(17)21)14-10-6-3-7-11-14/h2-11H,12H2,1H3/b19-16-
Canonical SMILES:
S1\C(N(C([C@@](C1)(C)Br)=O)c1ccccc1)=N/c1ccccc1
1.Prevention of ocular inflammation induced by lens protein, endotoxin, and interleukin-1 with synthetic interleukin-1 blockers.
Chiou GC;Yao QS;Okawara T J Ocul Pharmacol. 1994 Fall;10(3):577-86.
It is well known that corticosteroids are potent anti-inflammatory agents, yet they produce serious side effects. Although arachidonate metabolite blockers have been developed for the treatment of inflammation, they are much less potent than corticosteroids. Furthermore, they still process serious side effects. In search of potent and safe non-steroidal anti-inflammatory agents (NSAIA), interleukin-1 (IL-1) blockers have been developed. Among 121 CK-analogs studied, CK-17, CK-101A and CK103A have been identified as promising anti-inflammatory agents as potent as prednisolone in inhibiting lens proteins-induced inflammation and twice as potent as prednisolone in inhibiting endotoxin-and IL-1-induced uveitis. No serious side effects could be noticed with the doses of these compounds tested to date. These results indicate that the development of potent NSAIAs is feasible. Moreover, these compounds are not related to arachidonate metabolites.
2.Inhibitory effects of interleukin-1 blockers on corneal fibroblast proliferation.
Chen Z;Liu SX;Chiou GC J Ocul Pharmacol Ther. 1996 Summer;12(2):169-82.
The regulation of would healing is one of the most important fields of research in ophthalmology today. Rabbit corneal fibroblast cultures were used to study the effects of interleukin-1 (IL-1) blockers on the proliferation of fibroblasts which is closely related to the wound healing. It was found that IL-1 blockers, such as CK-17, CK-101A, CK-2 and CK-103A, suppress fibroblast proliferation in a concentration-dependent manner. DNA synthesis was significantly inhibited by CK-17 and CK-103A but not by CK-101A and CK1-102. Although the synthesis of mRNA was reduced by all CK-compounds at most concentration tested, the synthesis of protein was only slightly reduced or unaffected. These results indicate that CK-compounds are potent fibroblast inhibitors but not cytolytic agents.
3.Effects of interleukin-1 blockers on ophthalmic wound healing in a rabbit model of trabeculectomy.
Schwade ND;Chiou GC J Ocul Pharmacol Ther. 1995 Summer;11(2):125-34.
A trabeculectomy model was used to test the efficacy of some Interleukin-1 blockers on the modulation of ophthalmic wound healing in the pigmented rabbit. The corticosteroid, methyl prednisolone, was used as a positive control and was effective in prolonging the time to failure of the trabeculectomy by 21%. The experimental compounds CK-17, CK-101A, CK-102 and CK-103A were more efficacious than vehicle control at prolonging the number of days before failure of the trabeculectomy by 55%, 55%, 30% and 79%, respectively. The CK- compounds increased the amount of time before failure of the fistula, with no side effects at the doses tested to date.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Interleukin Related Products


CAS 186763-78-0 Ginsenoside Rg5

Ginsenoside Rg5
(CAS: 186763-78-0)

Ginsenoside Rg5, a main constituent isolated from red ginseng, exhibits anti-inflammatory property as in LPS-stimulated alveolar macrophages it inhibited the ex...

CAS 870087-36-8 Apilimod mesylate

Apilimod mesylate
(CAS: 870087-36-8)

The mesylate salt form of Apilimod. Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with ...

CAS 114727-43-4 SU 5201

SU 5201
(CAS: 114727-43-4)

SU 5201 is an inhibitor of IL-2 production.

CAS 2826-26-8 Tyrphostin A1

Tyrphostin A1
(CAS: 2826-26-8)

Tyrphostin A1, can be as a negative control for inhibition of EGFR (IC50 >1250 µM) and was shown to inhibit the tyrosine phosphorylation of IL-2 stimulated Tyk-...

CAS 210825-31-3 CP 424174

CP 424174
(CAS: 210825-31-3)

CP 424174 has been found to be an inhibitor of stimulus-coupled IL-1β post-translational processing.

CAS 849776-05-2 Ladarixin

Ladarixin
(CAS: 849776-05-2)

Ladarixin is Interleukin 8A and Interleukin 8B receptor antagonist. IL-8A and IL-8B inhibition blocks and reverses type 1 diabetes in mice. In Dec 2015, Phase-I...

CAS 755013-59-3 Veledimex racemate

Veledimex racemate
(CAS: 755013-59-3)

Veledimex racemate is the racemate of veledimex. Veledimex is an orally active small molecule diacylhydrazine and controls the expression of the target gene.

Ustekinumab
(CAS: 815610-63-0)

Ustekinumab is a human monoclonal antibody approved for the treatment of psoriasis and Crohn's disease. Ustekinumab acts via blocking IL-12 and IL-23.

Chemical Structure

CAS 86727-00-6 CK 17

Quick Inquiry

Verification code

Featured Items